Health Care Delivery

Designated teams, standardized SOPs, and scalable workflows are essential before a community practice's first bispecific dose.

FTC settles with CVS Caremark over insulin pricing, projecting $8.5 billion in patient savings over 10 years and mandating rebate and access reforms.

Respiratory rehabilitation improved exercise capacity in patients with COPD with and without suspected pulmonary hypertension.

New topicals, orals, and biologics are expanding chronic hand eczema treatment, but phenotype-specific data gaps remain.

KFF poll links social media use and not having a trusted doctor to vaccine myth beliefs, fueling COVID-19 and measles risk.

CMS's enforcement surge has put every Medicaid Fraud Control Unit under review, but experts say the bigger driver of coverage loss may be red tape.

New Legionnaires disease cases in NYC's Upper East Side cluster have declined as officials continue cooling tower remediation and investigation.

June author Erin L. Duffy, PhD, MPH, discusses her study showing nonprofit and system-affiliated hospitals provide greater access to translated financial assistance documents.

The FDA approved LEQEMBI IQLIK for once-weekly at-home subcutaneous initiation in early Alzheimer's disease based on IV and extension study data.

In this study, 13% of patients who stopped heart failure medications after successful AF ablation had HF deterioration vs none who continued treatment.

Paul Hahn, MD, on what separates practice-changing retina therapies from niche ones, plus gene therapy and home-monitoring hurdles.

Kerry Rogers, MD, weighs sequencing risk against daily adverse effects like bruising and joint pain that quietly influence BTK inhibitor decisions.

Pharmacy eases lung cancer costs; pediatric cancer erases 40% income; BTKis widen CLL access; hospitals lag on translated aid; MN mandate ends NGS denials.

Stefanie Houseknecht, PharmD, discusses patient education, financial barriers, and pharmacy's expanding role in precision lung cancer care.

COVID-19-related Medicare spending and health care use declined after acute infection, with minimal excess costs by weeks 13 to 40 after diagnosis.

Explore the biggest FDA PDUFA decisions expected in 2026, including gedatolisib, iberdomide, zidesamtinib, bepirovirsen, and anito-cel.

The expanded approval, based on the phase 3 WIL-33 trial, gives children with von Willebrand disease access to routine bleeding prophylaxis.

Large biobank study suggests a polygenic risk score may improve prediction of idiopathic pulmonary fibrosis diagnosis and outcomes.

Ebola cases hit 1708 as unpaid health workers strike, further straining an outbreak response the World Health Organization says is outpacing containment.

Carl Regillo, MD, on missed wet AMD injections, treatment switching, and how gene therapy could ease chronic burden.

Bhavana Bhatnagar, DO, who moved from academic to community oncology, shares why stronger academic-community partnerships are essential for patient care.

Jody Agena, PharmD, discusses staffing, communication, and operational readiness for implementing complex oncology therapies.

A secret shopper study found 9 in 10 online GLP-1 sellers issued prescriptions, often with minimal screening for eating disorders or clinical risk.

Real-world data show patients with MASH reach cirrhosis in just 16 months, fueling calls for wider use of fibrosis biomarkers like FIB-4.

Minhee Kang, PharmD, explains how oncology pharmacists translate clinical research into safe, coordinated cancer care.